Preclinical studies of FDA-approved small-molecules implementing lysosomal activity in a mouse model of MPSIIIA

Awardee: Diego Luis Medina

Institution: Telethon Institute of Genetics and Medicine (TIGEM)

Award Amount: $$55,992

Funding Period: February 1, 2019 - January 31, 2020

Previous
Previous

Expanding the Breadth of Metabolite Analysis for Snyder Robinson Syndrome

Next
Next

Generation of lysosomal enzyme variants with enhanced therapeutic potential for the treatment of MPS